MEDIA RELEASE

SAHPRA and the Pfizer Booster (3rd dose) Vaccine

Embargo: Immediate release

Pretoria, 26 November 2021- SAHPRA has received an application for the Pfizer Comirnaty Booster/3rddose vaccine on 17 November 2021.

This is for the homologous booster regimen, not a mix-and-match approach.

SAHPRA will now commence with the assessment of data for the safety and efficacy of the third dose.

The outcome of the assessment will be communicated in due course.

Issued by:

Dr Boitumelo Semete

CEO

Boitumelo.semete@sahpra.org.za

For further enquiries /information contact:

Media contact:

Mr Yuven Gounden

Cell: 066 1202 669

E-mail: yuveng@sahpra.org.za

About SAHPRA:

SAHPRA is tasked with regulating (monitoring, evaluating, investigating, inspecting and registering) all health products. This includes clinical trials, complementary medicines, medical devices and in-vitro diagnostics (IVDs). Furthermore, SAHPRA has the added responsibility of overseeing radiation

control in South Africa. SAHPRA's mandate is outlined in the Medicines and Related Substances Act (Act No 101 of 1965 as amended) as well as the Hazardous Substances Act (Act No 15 of 1973).

SAHPRA has three pillars to ensure that medicines, medical devices and IVDs meet the requisite standards to protect the health and well-being of all who reside in South Africa:

- Safety
- Efficacy
- Quality

It is these three pillars that define the ethos of SAHPRA.